Precigen, Inc. PGEN

PGEN Company Overview

Precigen, Inc. is a clinical-stage biotechnology company focused on advancing gene and cell-based therapies for cancer, rare diseases, and immune-related disorders. The company operates primarily within the biotechnology and genetic medicine industries, with an emphasis on developing proprietary platforms designed to improve the safety, precision, and scalability of gene expression and cellular engineering.

The company’s primary value drivers are its therapeutic development programs derived from its internal technology platforms, including AdenoVerse, UltraCAR-T, and ActoBiotics. Precigen serves oncology-focused clinical markets and specialty therapeutic areas with high unmet medical need. The company traces its origins to 1998 and was formerly known as Intrexon Corporation before rebranding as Precigen, Inc. in 2020, reflecting a strategic shift toward internally developed, clinically focused genetic medicines.